نتایج جستجو برای: hiv 1 dna vaccine

تعداد نتایج: 3346593  

2014
Viraj Kulkarni Antonio Valentin Margherita Rosati Morgane Rolland James I. Mullins George N. Pavlakis Barbara K. Felber Geetha P. Bansal

To target immune responses towards invariable regions of the virus, we engineered DNA-based immunogens encoding conserved elements (CE) of HIV-1 p24gag. This conserved element vaccine is designed to avoid decoy epitopes by focusing responses to critical viral elements. We previously reported that vaccination of macaques with p24CE DNA induced robust cellular immune responses to CE that were not...

Journal: :The Journal of infectious diseases 2013
Joseph P Casazza Kathryn A Bowman Selorm Adzaku Emily C Smith Mary E Enama Robert T Bailer David A Price Emma Gostick Ingelise J Gordon David R Ambrozak Martha C Nason Mario Roederer Charla A Andrews Frank M Maldarelli Ann Wiegand Mary F Kearney Deborah Persaud Carrie Ziemniak Raphael Gottardo Julie E Ledgerwood Barney S Graham Richard A Koup

BACKGROUND The licensing of herpes zoster vaccine has demonstrated that therapeutic vaccination can help control chronic viral infection. Unfortunately, human trials of immunodeficiency virus (HIV) vaccine have shown only marginal efficacy. METHODS In this double-blind study, 17 HIV-infected individuals with viral loads of <50 copies/mL and CD4(+) T-cell counts of >350 cells/µL were randomly ...

2011
Simon M. Agwale Joseph C. Forbi Frank Notka Terri Wrin Jens Wild Ralf Wagner Hans Wolf

Creation of an effective vaccine for HIV has been an elusive goal of the scientific community for almost 30 years. Neutralizing antibodies are assumed to be pivotal to the success of a prophylactic vaccine but previous attempts to make an immunogen capable of generating neutralizing antibodies to primary "street strain" isolates have resulted in responses of very limited breadth and potency. Th...

Journal: :Virology 2002
C Jane Dale Xiaosong Song Liu Robert De Rose Damian F J Purcell Jenny Anderson Yan Xu Graham R Leggatt Ian H Frazer Stephen J Kent

Vaccines to efficiently block or limit sexual transmission of both HIV and human papilloma virus (HPV) are urgently needed. Chimeric virus-like-particle (VLP) vaccines consisting of both multimerized HPV L1 proteins and fragments of SIV gag p27, HIV-1 tat, and HIV-1 rev proteins (HPV-SHIV VLPs) were constructed and administered to macaques both systemically and mucosally. An additional group of...

Journal: :The Journal of infectious diseases 2011
Lindsey R Baden William A Blattner Cecilia Morgan Yunda Huang Olivier D Defawe Magdalena E Sobieszczyk Nidhi Kochar Georgia D Tomaras M Juliana McElrath Nina Russell Kara Brandariz Massimo Cardinali Barney S Graham Dan H Barouch Raphael Dolin

BACKGROUND To investigate the potential immunostimulatory effect of interleukin (IL) 2 as a human immunodeficiency virus type 1 (HIV-1) vaccine adjuvant, we conducted a study of a plasmid coding for a fusion protein of IL-2 and immunoglobulin (IL-2/Ig). METHODS This phase I trial evaluated an HIV-1 DNA vaccine with the plasmid cytokine adjuvant (IL-2/Ig) in 70 HIV-negative adults. Subjects re...

Journal: :Journal of virology 2004
Norman L Letvin Yue Huang Bimal K Chakrabarti Ling Xu Michael S Seaman Kristin Beaudry Birgit Korioth-Schmitz Faye Yu Daniela Rohne Kristi L Martin Ayako Miura Wing-Pui Kong Zhi-Yong Yang Rebecca S Gelman Olga G Golubeva David C Montefiori John R Mascola Gary J Nabel

Because a strategy to elicit broadly neutralizing anti-human immunodeficiency virus type 1 (HIV-1) antibodies has not yet been found, the role of an Env immunogen in HIV-1 vaccine candidates remains undefined. We sought to determine whether an HIV-1 Env immunogen genetically disparate from the Env of the challenge virus can contribute to protective immunity. We vaccinated Indian-origin rhesus m...

2013
Kathryn E Stephenson Dan H Barouch

A global human immunodeficiency virus-1 (HIV-1) vaccine will have to elicit immune responses capable of providing protection against a tremendous diversity of HIV-1 variants. In this review, we first describe the current state of the HIV-1 vaccine field, outlining the immune responses that are desired in a global HIV-1 vaccine. In particular, we emphasize the likely importance of Env-specific n...

2011
Daniela Santoro Rosa Susan Pereira Ribeiro Rafael Ribeiro Almeida Eliane Conti Mairena Edilberto Postól Jorge Kalil Edecio Cunha-Neto

T-cell based vaccines against HIV have the goal of limiting both transmission and disease progression by inducing broad and functionally relevant T cell responses. Moreover, polyfunctional and long-lived specific memory T cells have been associated to vaccine-induced protection. CD4(+) T cells are important for the generation and maintenance of functional CD8(+) cytotoxic T cells. We have recen...

2017
Qian Wang Yanyan Dai Zhiwu Sun Xiaojie Su Yufeng Yu Chen Hua Wei Xu Shibo Jiang Lu Lu

Dear Editor, According to UNAIDS, 435 million people have died of AIDS, and about 36.7 million people were still living with HIV worldwide by the end of 2015. Therefore, it is essential to develop an efficacious vaccine to prevent HIV infection. However, even with numerous HIV vaccine clinical trials having been completed, no HIV vaccine has successfully emerged.1,2 Notably, the RV144 HIV vacci...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید